CTXR
Citius Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.23
P/S
2.44
EV/EBITDA
-0.10
DCF Value
$0.92
FCF Yield
-362.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.4%
Operating Margin
-950.9%
Net Margin
-909.9%
ROE
-52.5%
ROA
-25.6%
ROIC
-36.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.9M | $-8.2M | $-0.38 |
| Q4 2025 | $0.00 | $-8.0M | $-0.44 |
| FY 2025 | $0.00 | $-37.4M | $-3.38 |
| Q3 2025 | $0.00 | $-8.8M | $-0.80 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.38
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.